Researchers at the University of North Carolina at Chapel Hill Gillings School of Global Public Health and their colleagues at the University of Texas at Austin and the National Institutes of Health Vaccine Research Center have discovered an antibody that broadly inhibits multiple strains of pandemic norovirus, a major step forward in the development of an effective vaccine for the dreaded stomach virus.
* This article was originally published here
